

**Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development, Biopharma Production, Research, Diagnostics), End User (Biotech, CROs) - Global Forecast to 2027**

Market Report | 2022-11-04 | 237 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The global recombinant proteins market is projected to reach USD 2.4 billion by 2027 from USD 1.4 billion in 2022, at a CAGR of 11.4% during the forecast period. The market growth is primarily driven by factors such as increasing government investments and R&D expenditure in pharmaceutical & biotechnology companies and academic research institutes alongside the high prevalence of chronic and infectious diseases resulting in the need for recombinant proteins for crucial diagnostics. However, flocking to the market with competitively priced products and labor-intensive processes with low yields of recombinant protein may restrict market growth to a certain extent

"The pharmaceutical & biopharmaceutical companies segment is expected to dominate the market during the forecast period." Based on end users, the recombinant proteins market is segmented into pharmaceutical & biopharmaceutical companies, biotechnology companies, academic research institutes, contract research organizations, and other end users. Pharmaceutical & biopharmaceutical companies accounted for the largest share of the end user market in 2020. The large share of this segment is attributed to the role of recombinant proteins as a crucial component of most small molecule drug discovery programs, as well as the requirement of recombinant protein in drug discovery for the screening of the structural and mechanistic studies of new drug applications. Also, factors such as the patent expiration of blockbuster drugs impact the market growth positively.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

"Vaccine segment will witness the second highest growth in the recombinant proteins market during the forecast period."

Based on type, the drug discovery & development market is segmented into biologics, vaccines, and cell & gene therapy. Vaccine accounted for the second largest share of the drug discovery & development application for the recombinant proteins market and is expected to register the second highest CAGR during the forecast period. The large share of the vaccine segment is attributed to the factors such increased incidence of diseases such as influenza, viral diseases and hepatitis. The emergence of such diseases has led to increased R&D activities to discover proactive vaccine and this is fueling the market growth for recombinant protein.

"North America will dominate the market during the forecast period."

Geographically, the recombinant proteins market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America accounted for the largest share of the recombinant proteins market. The large share of this region in the global market is attributed to the rising prevalence of infectious diseases and chronic conditions, growing R&D spending by the government and pharmaceutical industry, increasing research activities by biotechnology firms, and the presence of key market players.

The primary interviews conducted for this report can be categorized as follows:

- By Company Type - Tier 1: 36%, Tier 2: 45%, and Tier 3: 19%
- By Designation - C-level: 33%, D-level: 40%, and Others: 27%
- By Region - North America: 36%, Europe: 28%, Asia Pacific: 19%, Latin America: 10%, and Middle East and Africa 7%.

List of Companies Profiled in the Report

- Thermo Fisher Scientific Inc. (US)
- Miltenyi Biotech (Germany)
- Sino Biological Inc. (China)
- Merck KGaA (Germany)
- Abcam plc (UK)
- Biolegend (US)
- Bio-Rad Laboratories, Inc. (US)
- GenScript Biotech Corporation (China)
- Enzo Life Sciences, Inc. (US)
- BPS Bioscience, Inc. (US)
- Proteintech Group, Inc. (US)
- Abnova Corporation (Taiwan)
- R&D Systems (US)
- STEMCELL Technologies Inc (Canada)
- RayBiotech Inc (US)
- CellGenix GmbH (Germany)
- ACROBiosystems (US)
- ProSpec-TechnoGene Ltd. (Israel)
- Neuromics (US)
- Laurus Bio (India)
- Icosagen AS (US)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- ProteoGenix (France)
- United States Biological (US)
- StressMarq Biosciences Inc (Canada)
- Aviva Systems Biology Corporation (US)

**Research Coverage:**

This report provides a detailed picture of the global recombinant proteins market. It aims at estimating the size and future growth potential of the market across different segments, such as product, application, end user, and region. The report also analyzes factors (such as drivers, restraints, challenges, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total recombinant proteins market. The report forecasts the revenue of the market segments with respect to five major regions.

**Reasons to Buy the Report:**

The report provides insights on the following pointers:

- **Market Penetration:** Comprehensive information on recombinant proteins offered by the top 25 players in the recombinant proteins market. The report analyses the recombinant proteins market by product, application, end user, and region.
- **Market Development:** Comprehensive information about lucrative emerging markets. The report analyzes the markets for various recombinant proteins across key geographic regions.
- **Market Diversification:** Exhaustive information about new products, untapped geographies, recent developments, and investments in the recombinant proteins market.
- **Competitive Assessment:** In-depth assessment of market ranking and strategies of the leading players in the recombinant proteins market.

**Table of Contents:**

- 1 INTRODUCTION 32
- 1.1 STUDY OBJECTIVES 32
- 1.2 MARKET DEFINITION 32
- 1.2.1 INCLUSIONS AND EXCLUSIONS 33
- 1.3 MARKET SCOPE 34
- FIGURE 1 RECOMBINANT PROTEINS MARKET 34
- 1.4 YEARS CONSIDERED 35
- 1.5 CURRENCY CONSIDERED 35
- 1.6 LIMITATIONS 35
- 1.7 STAKEHOLDERS 35
- 1.8 SUMMARY OF CHANGES 36
- 2 RESEARCH METHODOLOGY 37
- 2.1 RESEARCH DATA 37
- FIGURE 2 RESEARCH DESIGN 37
- 2.1.1 SECONDARY DATA 38

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.1.1.1	Secondary sources	38
2.1.2	PRIMARY DATA	38
2.1.2.1	Key data from primary sources	39
FIGURE 3	BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION	39
2.2	MARKET SIZE ESTIMATION	40
2.2.1	BOTTOM-UP APPROACH	40
FIGURE 4	MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH	40
2.2.2	TOP-DOWN APPROACH	41
FIGURE 5	MARKET SIZE ESTIMATION: TOP-DOWN APPROACH	41
2.2.3	GROWTH FORECAST	41
2.3	MARKET BREAKDOWN AND DATA TRIANGULATION	42
FIGURE 6	DATA TRIANGULATION METHODOLOGY	42
2.4	ASSUMPTIONS	43
3	EXECUTIVE SUMMARY	44
FIGURE 7	RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)	44
FIGURE 8	RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)	45
FIGURE 9	RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)	45
FIGURE 10	RECOMBINANT PROTEINS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)	46
4	PREMIUM INSIGHTS	48
4.1	RECOMBINANT PROTEINS MARKET OVERVIEW	48
FIGURE 12	INCREASING GOVERNMENT INVESTMENTS AND RISING FOCUS ON PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH	48
4.2	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION AND COUNTRY (2022)	49
FIGURE 13	DRUG DISCOVERY AND DEVELOPMENT SEGMENT TO ACCOUNT FOR LARGEST SHARE IN ASIA PACIFIC MARKET	49
4.3	RECOMBINANT PROTEINS MARKET, BY END USER, 2022-2027	50
FIGURE 14	PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES TO FORM LARGEST END-USER SEGMENT FOR RECOMBINANT PROTEINS	50
4.4	RECOMBINANT PROTEINS MARKET: GEOGRAPHIC SNAPSHOT	50
FIGURE 15	JAPAN TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD	50
5	MARKET OVERVIEW	51
5.1	INTRODUCTION	51
5.2	MARKET DYNAMICS	51
FIGURE 16	RECOMBINANT PROTEINS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	51
5.2.1	DRIVERS	52
5.2.1.1	Rising government funding and increasing R&D expenditure in pharmaceutical and biotechnology companies	52
TABLE 1	GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2022)	52
5.2.1.2	High prevalence of infectious and chronic diseases	53
5.2.1.3	Growing industry-academia collaborations	53
5.2.1.4	Patent expiry of biologics	54
5.2.2	RESTRAINTS	54
5.2.2.1	Declining cost of recombinant proteins	54
5.2.2.2	Stringent regulatory scenario	54
5.2.3	OPPORTUNITIES	55
5.2.3.1	Emerging economies	55
5.2.3.2	Rising focus on personalized medicine and protein therapeutics	56
TABLE 2	COMMERCIALIZED RECOMBINANT PROTEINS USED IN MEDICINE	56

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.2.3.3	Increasing focus on biomarker discovery	57
5.2.4	CHALLENGES	57
5.2.4.1	Complications in large-scale production	57
5.3	PRICING ANALYSIS	58
5.3.1	AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYER	58
TABLE 3	PRICE OF RECOMBINANT PROTEINS, BY KEY PLAYER (USD)	58
5.3.2	AVERAGE SELLING PRICE TREND	58
TABLE 4	PRICE OF RECOMBINANT PROTEINS: INDUSTRIAL VS. PHARMACEUTICAL	59
5.4	STAKEHOLDER ANALYSIS	59
FIGURE 17	RECOMBINANT PROTEINS MARKET: STAKEHOLDER ANALYSIS	61
5.5	VALUE CHAIN ANALYSIS	61
FIGURE 18	VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES	61
5.6	ECOSYSTEM ANALYSIS	62
FIGURE 19	BIOTECHNOLOGY ECOSYSTEM ANALYSIS: RECOMBINANT PROTEINS FORM AN INTEGRAL PART OF BIOTECHNOLOGY	62
5.7	REGULATORY ANALYSIS	63
5.7.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	63
TABLE 5	NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	63
TABLE 6	EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	63
TABLE 7	ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	64
TABLE 8	REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	64
5.8	PORTER'S FIVE FORCES ANALYSIS	65
TABLE 9	RECOMBINANT PROTEINS MARKET: PORTER'S FIVE FORCES ANALYSIS	65
5.8.1	THREAT OF NEW ENTRANTS	65
5.8.2	THREAT OF SUBSTITUTES	65
5.8.3	BARGAINING POWER OF BUYERS	66
5.8.4	BARGAINING POWER OF SUPPLIERS	66
5.8.5	INTENSITY OF RIVALRY	66
5.9	TECHNOLOGY ANALYSIS	67
5.10	PATENT ANALYSIS	68
FIGURE 20	TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR RECOMBINANT PROTEIN PATENTS (JANUARY 2012-OCTOBER 2022)	68
TABLE 10	INDICATIVE LIST OF PATENTS IN RECOMBINANT PROTEINS MARKET	69
5.11	KEY CONFERENCES AND EVENTS IN 2022-2023	70
TABLE 11	RECOMBINANT PROTEINS MARKET: LIST OF CONFERENCES AND EVENTS	70
5.12	KEY STAKEHOLDERS AND BUYING CRITERIA	71
FIGURE 21	INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF RECOMBINANT PROTEIN PRODUCTS	71
5.13	KEY BUYING CRITERIA OF END USERS	71
FIGURE 22	BUYING CRITERIA OF END USERS FOR RECOMBINANT PROTEINS	71
6	RECOMBINANT PROTEINS MARKET, BY PRODUCT	72
6.1	INTRODUCTION	73
6.2	GROWTH FACTORS AND CHEMOKINES	74
6.2.1	GROWTH FACTORS AND CHEMOKINES ACCOUNTED FOR LARGEST MARKET SHARE IN 2021	74
TABLE 13	GROWTH FACTORS AND CHEMOKINES MARKET, BY REGION, 2020-2027 (USD MILLION)	75
TABLE 14	NORTH AMERICA: GROWTH FACTORS AND CHEMOKINES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	75
TABLE 15	EUROPE: GROWTH FACTORS AND CHEMOKINES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	76
TABLE 16	ASIA PACIFIC: GROWTH FACTORS AND CHEMOKINES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	76
6.3	IMMUNE RESPONSE PROTEINS	77

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

### 6.3.1 IMMUNE CHECKPOINT PROTEINS PLAY KEY ROLE IN CANCER IMMUNOTHERAPY 77

TABLE 17 IMMUNE RESPONSE PROTEINS MARKET, BY REGION, 2020-2027 (USD MILLION) 77

TABLE 18 NORTH AMERICA: IMMUNE RESPONSE PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 78

TABLE 19 EUROPE: IMMUNE RESPONSE PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 78

TABLE 20 ASIA PACIFIC: IMMUNE RESPONSE PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 78

### 6.4 STRUCTURAL PROTEINS 79

6.4.1 STRUCTURAL PROTEINS UTILIZED IN CELL CULTURE APPLICATIONS AS ATTACHMENT FACTORS 79

TABLE 21 STRUCTURAL PROTEINS MARKET, BY REGION, 2020-2027 (USD MILLION) 79

TABLE 22 NORTH AMERICA: STRUCTURAL PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 80

TABLE 23 EUROPE: STRUCTURAL PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 80

TABLE 24 ASIA PACIFIC: STRUCTURAL PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 80

### 6.5 MEMBRANE PROTEINS 81

6.5.1 MEMBRANE PROTEINS REGULATE PROCESSES THAT HELP BIOLOGICAL CELLS SURVIVE 81

TABLE 25 MEMBRANE PROTEINS MARKET, BY REGION, 2020-2027 (USD MILLION) 81

TABLE 26 NORTH AMERICA: MEMBRANE PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 82

TABLE 27 EUROPE: MEMBRANE PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 82

TABLE 28 ASIA PACIFIC: MEMBRANE PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 82

### 6.6 KINASE PROTEINS 83

6.6.1 KINASE PROTEINS PLAY KEY ROLE IN SIGNAL TRANSDUCTION PATHWAYS 83

TABLE 29 KINASE PROTEINS MARKET, BY REGION, 2020-2027 (USD MILLION) 83

TABLE 30 NORTH AMERICA: KINASE PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 83

TABLE 31 EUROPE: KINASE PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 84

TABLE 32 ASIA PACIFIC: KINASE PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 84

### 6.7 REGULATORY PROTEINS 85

6.7.1 REGULATORY PROTEINS HELP UNDERSTAND CELL CYCLE REGULATION AND CARCINOGENESIS 85

TABLE 33 REGULATORY PROTEINS MARKET, BY REGION, 2020-2027 (USD MILLION) 85

TABLE 34 NORTH AMERICA: REGULATORY PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 85

TABLE 35 EUROPE: REGULATORY PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 86

TABLE 36 ASIA PACIFIC: REGULATORY PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 86

### 6.8 RECOMBINANT METABOLIC ENZYMES 87

6.8.1 ENZYMES REGULATE PROTEIN INTERACTIONS 87

TABLE 37 RECOMBINANT METABOLIC ENZYMES MARKET, BY REGION, 2020-2027 (USD MILLION) 87

TABLE 38 NORTH AMERICA: RECOMBINANT METABOLIC ENZYMES MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 87

TABLE 39 EUROPE: RECOMBINANT METABOLIC ENZYMES MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 88

TABLE 40 ASIA PACIFIC: RECOMBINANT METABOLIC ENZYMES MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 88

### 6.9 ADHESION MOLECULES AND RECEPTORS 89

6.9.1 CELL ADHESION MOLECULES FACILITATE EXTRACELLULAR MATRIX (ECM) INTERACTIONS 89

TABLE 41 ADHESION MOLECULES AND RECEPTORS MARKET, BY REGION, 2020-2027 (USD MILLION) 89

TABLE 42 NORTH AMERICA: ADHESION MOLECULES AND RECEPTORS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 89

TABLE 43 EUROPE: ADHESION MOLECULES AND RECEPTORS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 90

TABLE 44 ASIA PACIFIC: ADHESION MOLECULES AND RECEPTORS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 90

### 6.10 OTHER RECOMBINANT PROTEINS 91

TABLE 45 OTHER RECOMBINANT PROTEINS MARKET, BY REGION, 2020-2027 (USD MILLION) 91

TABLE 46 NORTH AMERICA: OTHER RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 91

TABLE 47 EUROPE: OTHER RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 92

TABLE 48 ASIA PACIFIC: OTHER RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 92

7 RECOMBINANT PROTEINS MARKET, BY APPLICATION 93

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## 7.1 INTRODUCTION 94

TABLE 49 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 94

### 7.2 DRUG DISCOVERY AND DEVELOPMENT 94

TABLE 50 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2020-2027 (USD MILLION) 95

TABLE 51 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2020-2027 (USD MILLION) 95

TABLE 52 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2020-2027 (USD MILLION) 95

TABLE 53 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2020-2027 (USD MILLION) 96

TABLE 54 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY TYPE, 2020-2027 (USD MILLION) 96

#### 7.2.1 BIOLOGICS 96

7.2.1.1 Biologics are used to treat cancer, autoimmune diseases, and other serious disorders 96

TABLE 55 RECOMBINANT PROTEIN BIOLOGIC DRUGS 97

TABLE 56 RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY REGION, 2020-2027 (USD MILLION) 97

TABLE 57 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2020-2027 (USD MILLION) 98

TABLE 58 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2020-2027 (USD MILLION) 98

TABLE 59 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2020-2027 (USD MILLION) 98

#### 7.2.2 VACCINES 99

7.2.2.1 Rising incidence of infectious diseases to boost market growth for vaccines 99

TABLE 60 RECOMBINANT PROTEINS MARKET FOR VACCINES, BY REGION, 2020-2027 (USD MILLION) 99

TABLE 61 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2020-2027 (USD MILLION) 100

TABLE 62 EUROPE: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2020-2027 (USD MILLION) 100

TABLE 63 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2020-2027 (USD MILLION) 100

#### 7.2.3 CELL AND GENE THERAPY 101

7.2.3.1 Stem cell therapy and CAR T-cell therapies have boosted demand for recombinant proteins 101

TABLE 64 RECOMBINANT PROTEINS MARKET FOR CELL AND GENE THERAPY, BY REGION, 2020-2027 (USD MILLION) 101

TABLE 65 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 102

TABLE 66 EUROPE: RECOMBINANT PROTEINS MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 102

TABLE 67 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 102

### 7.3 ACADEMIC RESEARCH STUDIES 103

7.3.1 RECOMBINANT PROTEINS HAVE APPLICATIONS IN MOLECULAR AND GENE EXPRESSION STUDIES 103

TABLE 68 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY REGION, 2020-2027 (USD MILLION) 103

TABLE 69 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2020-2027 (USD MILLION) 104

TABLE 70 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2020-2027 (USD MILLION) 104

TABLE 71 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2020-2027 (USD MILLION) 104

### 7.4 BIOPHARMACEUTICAL PRODUCTION 105

7.4.1 RECOMBINANT PROTEINS WIDELY USED FOR DEVELOPMENT OF PROTEIN-BASED DRUGS 105

TABLE 72 RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2020-2027 (USD MILLION) 105

TABLE 73 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2020-2027 (USD MILLION) 105

TABLE 74 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2020-2027 (USD

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MILLION)□106

TABLE 75□ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2020-2027 (USD MILLION)□106

7.5□BIOTECHNOLOGY RESEARCH□106

7.5.1□INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS TO DRIVE MARKET GROWTH□106

TABLE 76□RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY REGION, 2020-2027 (USD MILLION)□107

TABLE 77□NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2020-2027 (USD MILLION)□107

TABLE 78□EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2020-2027 (USD MILLION)□108

TABLE 79□ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2020-2027 (USD MILLION)□108

7.6□DIAGNOSTICS□109

7.6.1□HIGH SENSITIVITY AND SPECIFICITY OF RECOMBINANT PROTEIN-BASED DIAGNOSTICS TO INFLUENCE MARKET GROWTH□109

TABLE 80□RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY REGION, 2020-2027 (USD MILLION)□109

TABLE 81□NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)□109

TABLE 82□EUROPE: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)□110

TABLE 83□ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)□110

7.7□OTHER APPLICATIONS□111

TABLE 84□RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)□111

TABLE 85□NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)□111

TABLE 86□EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)□112

TABLE 87□ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)□112

8□RECOMBINANT PROTEINS MARKET, BY END USER□113

8.1□INTRODUCTION□114

TABLE 88□RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION)□114

8.2□PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES□114

8.2.1□PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES ARE LARGEST END USERS OF RECOMBINANT PROTEINS□114

TABLE 89□RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020-2027 (USD MILLION)□115

TABLE 90□NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)□115

TABLE 91□EUROPE: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)□116

TABLE 92□ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)□116

8.3□BIOTECHNOLOGY COMPANIES□116

8.3.1□INCREASING NUMBER OF PROJECTS FOR PROTEIN-BASED RESEARCH DRIVING MARKET GROWTH□116

TABLE 93□RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2027 (USD MILLION)□117

TABLE 94□NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)□117

TABLE 95□EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)□117

TABLE 96□ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)□118

8.4□ACADEMIC RESEARCH INSTITUTES□118

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

#### 8.4.1 GROWING GOVERNMENT INVESTMENTS TO PROPEL MARKET GROWTH 118

TABLE 97 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020-2027 (USD MILLION) 119

TABLE 98 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION) 119

TABLE 99 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION) 119

TABLE 100 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION) 120

#### 8.5 CONTRACT RESEARCH ORGANIZATIONS 120

##### 8.5.1 INCREASING OUTSOURCING OF SERVICES TO CROS DRIVING MARKET GROWTH 120

TABLE 101 RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020-2027 (USD MILLION) 121

TABLE 102 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION) 121

TABLE 103 EUROPE: RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION) 121

TABLE 104 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION) 122

#### 8.6 OTHER END USERS 122

TABLE 105 RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY REGION, 2020-2027 (USD MILLION) 122

TABLE 106 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2020-2027 (USD MILLION) 123

TABLE 107 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2020-2027 (USD MILLION) 123

TABLE 108 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2020-2027 (USD MILLION) 123

#### 9 RECOMBINANT PROTEINS MARKET, BY REGION 124

##### 9.1 INTRODUCTION 125

TABLE 109 RECOMBINANT PROTEINS MARKET, BY REGION, 2020-2027 (USD MILLION) 125

##### 9.2 NORTH AMERICA 126

FIGURE 23 NORTH AMERICA: RECOMBINANT PROTEINS MARKET SNAPSHOT 126

TABLE 110 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 127

TABLE 111 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 127

TABLE 112 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 128

TABLE 114 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION) 129

###### 9.2.1 US 129

9.2.1.1 US accounted for largest share of North American market 129

TABLE 115 US NIH BUDGET FOR VARIOUS DISCIPLINES, FY 2020 VS. FY 2021 (USD BILLION) 130

TABLE 116 US: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 130

TABLE 117 US: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 131

TABLE 118 US: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION) 131

TABLE 119 US: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION) 132

###### 9.2.2 CANADA 132

9.2.2.1 High prevalence of cancer and favorable funding scenario to support market growth 132

TABLE 120 CANADA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 133

TABLE 121 CANADA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 134

TABLE 122 CANADA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION) 134

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 123 CANADA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION) 135  
9.3 EUROPE 135

TABLE 124 EUROPE: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 136

TABLE 125 EUROPE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 136

TABLE 126 EUROPE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 137

TABLE 127 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION) 137

TABLE 128 EUROPE: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION) 138

9.3.1 GERMANY 138

9.3.1.1 Germany held largest share of European market in 2021 138

TABLE 129 GERMANY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 139

TABLE 130 GERMANY: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 139

TABLE 131 GERMANY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION) 140

TABLE 132 GERMANY: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION) 140

9.3.2 UK 140

9.3.2.1 Government initiatives to drive market growth in UK 140

TABLE 133 UK: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 141

TABLE 134 UK: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 142

TABLE 135 UK: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION) 142

TABLE 136 UK: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION) 143

9.3.3 FRANCE 143

9.3.3.1 Infrastructural development and rising life science R&D expected to support market growth 143

TABLE 137 FRANCE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 144

TABLE 138 FRANCE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 145

TABLE 139 FRANCE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION) 145

TABLE 140 FRANCE: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION) 146

9.3.4 ITALY 146

9.3.4.1 Life science research investments and favorable funding scenario to drive growth 146

TABLE 141 ITALY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 147

TABLE 142 ITALY: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 147

TABLE 143 ITALY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION) 148

TABLE 144 ITALY: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION) 148

9.3.5 SPAIN 148

9.3.5.1 Favorable scenario for research initiatives to propel market growth 148

TABLE 145 SPAIN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 149

TABLE 146 SPAIN: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 150

TABLE 147 SPAIN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION) 150

TABLE 148 SPAIN: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION) 151

9.3.6 REST OF EUROPE 151

TABLE 149 ROE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 152

TABLE 150 ROE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 152

TABLE 151 ROE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE,

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2020-2027 (USD MILLION) 153

TABLE 152 ROE: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION) 153

9.4 ASIA PACIFIC 154

TABLE 153 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 156

TABLE 154 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 156

TABLE 155 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 157

TABLE 156 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION) 157

TABLE 157 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION) 158

9.4.1 JAPAN 158

9.4.1.1 Advanced healthcare infrastructure to support market growth 158

TABLE 158 JAPAN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 159

TABLE 159 JAPAN: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 159

TABLE 160 JAPAN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION) 160

TABLE 161 JAPAN: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION) 160

9.4.2 CHINA 160

9.4.2.1 China to witness highest growth in Asia Pacific market 160

TABLE 162 CHINA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 161

TABLE 163 CHINA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 162

TABLE 164 CHINA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION) 162

TABLE 165 CHINA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION) 163

9.4.3 INDIA 163

9.4.3.1 Strong biopharmaceutical growth and rising demand for pharmaceuticals are key market drivers 163

TABLE 166 INDIA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 164

TABLE 167 INDIA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 165

TABLE 168 INDIA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION) 165

TABLE 169 INDIA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION) 166

9.4.4 REST OF ASIA PACIFIC 166

TABLE 170 ROAPAC: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 167

TABLE 171 ROAPAC: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 168

TABLE 172 ROAPAC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION) 168

TABLE 173 ROAPAC: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION) 169

9.5 LATIN AMERICA 169

9.5.1 GROWTH IN BIOPHARMACEUTICAL INDUSTRY TO DRIVE DEMAND FOR RECOMBINANT PROTEINS 169

TABLE 174 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 170

TABLE 175 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 171

TABLE 176 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION) 171

TABLE 177 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION) 172

9.6 MIDDLE EAST & AFRICA 172

9.6.1 INCREASING GOVERNMENT INVESTMENTS IN HEALTHCARE SECTOR AND GROWING PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH 172

TABLE 178 MIDDLE EAST & AFRICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 173

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 179	MIDDLE EAST & AFRICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	174
TABLE 180	MIDDLE EAST & AFRICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)	174
TABLE 181	MIDDLE EAST & AFRICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2020-2027 (USD MILLION)	175
?		
10	COMPETITIVE LANDSCAPE	176
10.1	OVERVIEW	176
FIGURE 25	KEY PLAYERS ADOPTED ORGANIC AND INORGANIC GROWTH STRATEGIES BETWEEN 2019 AND 2022	176
10.2	MARKET SHARE ANALYSIS	177
FIGURE 26	RECOMBINANT PROTEINS MARKET: MARKET SHARE ANALYSIS, 2021 (TOP 4 PLAYERS)	177
TABLE 182	RECOMBINANT PROTEINS MARKET: DEGREE OF COMPETITION	178
10.3	REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS	179
FIGURE 27	REVENUE SHARE ANALYSIS OF PLAYERS IN RECOMBINANT PROTEINS MARKET (TOP 4)	179
10.4	COMPANY EVALUATION MATRIX: KEY PLAYERS (2021)	180
10.4.1	VENDOR INCLUSION CRITERIA	180
10.4.2	STARS	180
10.4.3	EMERGING LEADERS	180
10.4.4	PERVASIVE PLAYERS	180
10.4.5	PARTICIPANTS	180
FIGURE 28	RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2021)	181
10.5	COMPANY EVALUATION MATRIX: START-UPS/SMES (2021)	182
10.5.1	PROGRESSIVE COMPANIES	182
10.5.2	STARTING BLOCKS	182
10.5.3	RESPONSIVE COMPANIES	182
10.5.4	DYNAMIC COMPANIES	182
FIGURE 29	RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2021)	183
10.6	COMPETITIVE BENCHMARKING OF TOP 25 COMPANIES	184
10.6.1	OVERALL FOOTPRINT OF TOP 25 COMPANIES	184
FIGURE 30	FOOTPRINT ANALYSIS OF KEY PLAYERS IN RECOMBINANT PROTEINS MARKET	184
10.7	COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES	185
TABLE 183	RECOMBINANT PROTEINS MARKET: DETAILED LIST OF KEY START-UPS/SMES	185
TABLE 184	RECOMBINANT PROTEINS MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES	186
10.8	COMPETITIVE SCENARIO	186
10.8.1	PRODUCT LAUNCHES AND APPROVALS (2019-2022)	186
10.8.2	DEALS (2019-2022)	187
10.8.3	EXPANSIONS (2019-2022)	188
?		
11	COMPANY PROFILES	189
11.1	KEY PLAYERS	189
	(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*	
11.1.1	BIO-TECHNE CORPORATION	189
TABLE 185	R&D SYSTEMS: BUSINESS OVERVIEW	189
FIGURE 31	BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2021)	190
11.1.2	THERMO FISHER SCIENTIFIC, INC.	194
TABLE 186	THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW	194
FIGURE 32	THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)	195

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.1.3	MERCK KGAA	198
	TABLE 187	MERCK KGAA: BUSINESS OVERVIEW
	FIGURE 33	MERCK KGAA: COMPANY SNAPSHOT (2021)
11.1.4	ABCAM PLC	202
	TABLE 188	ABCAM PLC: BUSINESS OVERVIEW
	FIGURE 34	ABCAM PLC: COMPANY SNAPSHOT (2021)
11.1.5	ABNOVA CORPORATION	205
	TABLE 189	ABNOVA CORPORATION: BUSINESS OVERVIEW
11.1.6	BIOLEGEND	207
	TABLE 190	BIOLEGEND: BUSINESS OVERVIEW
11.1.7	BIO-RAD LABORATORIES, INC.	209
	TABLE 191	BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
	FIGURE 35	BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
11.1.8	BPS BIOSCIENCE, INC.	211
	TABLE 192	BPS BIOSCIENCE, INC.: BUSINESS OVERVIEW
11.1.9	ENZO LIFE SCIENCES, INC.	213
	TABLE 193	ENZO LIFE SCIENCES, INC.: BUSINESS OVERVIEW
	FIGURE 36	ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2021)
11.1.10	GENSCRIPT BIOTECH CORPORATION	216
	FIGURE 37	GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2021)
11.1.11	MILTENYI BIOTEC	220
	TABLE 195	MILTENYI BIOTECH: BUSINESS OVERVIEW
11.1.12	PROTEINTECH GROUP	222
	TABLE 196	PROTEINTECH GROUP: BUSINESS OVERVIEW
11.1.13	SINO BIOLOGICAL INC.	224
	TABLE 197	SINO BIOLOGICAL INC.: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.		
11.2	OTHER PLAYERS	227
11.2.1	ACROBIOSYSTEMS	227
11.2.2	AVIVA SYSTEMS BIOLOGY CORPORATION	228
11.2.3	CELLGENIX GMBH	228
11.2.4	ICOSAGEN AS	229
11.2.5	NEUROMICS	230
11.2.6	PROSPEC-TECHNOGENE LTD.	231
11.2.7	PROTEOGENIX	232
11.2.8	RAYBIOTECH, INC.	233
11.2.9	LAURUS BIO (RICHCORE LIFESCIENCES PVT. LTD.)	234
11.2.10	STEMCELL TECHNOLOGIES INC.	235
11.2.11	STRESSMARQ BIOSCIENCES INC.	236
11.2.12	UNITED STATES BIOLOGICAL	237
12	APPENDIX	238
12.1	DISCUSSION GUIDE	238
12.2	KNOWLEDGE STORE: MARKETSSANDMARKETS' SUBSCRIPTION PORTAL	242
12.3	CUSTOMIZATION OPTIONS	244
12.4	RELATED REPORTS	244
12.5	AUTHOR DETAILS	245

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development, Biopharma Production, Research, Diagnostics), End User (Biotech, CROs) - Global Forecast to 2027**

Market Report | 2022-11-04 | 237 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Zip Code\*

Country\*

Date

2026-03-05

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)